Literature DB >> 6861430

Postmarketing studies of drug efficacy: when must they be randomized?

B L Strom, O S Miettinen, K L Melmon.   

Abstract

Mesh：

Year:  1983        PMID： 6861430     DOI： 10.1038/clpt.1983.119

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN： 0009-9236            Impact factor:   6.875


× No keyword cloud information.
  6 in total

Review 1.  Design issues for drug epidemiology.

Authors:  A D McMahon; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  2000-11       Impact factor: 4.335

Review 2.  Is there a hierarchy of methods in clinical research?

Authors:  J P Vandenbroucke
Journal:  Klin Wochenschr       Date:  1989-05-15

Review 3.  Developments in post-marketing comparative effectiveness research.

Authors:  S Schneeweiss
Journal:  Clin Pharmacol Ther       Date:  2007-06-06       Impact factor: 6.875

Review 4.  Techniques of postmarketing surveillance. An overview.

Authors:  J L Carson; B L Strom
Journal:  Med Toxicol       Date:  1986 Jul-Aug

5.  Reference-based pricing of prescription drugs: exploring the equivalence of angiotensin-converting-enzyme inhibitors.

Authors:  C Bourgault; E Elstein; J Le Lorier; S Suissa
Journal:  CMAJ       Date:  1999-08-10       Impact factor: 8.262

6.  Personalization of medicine requires better observational evidence.

Authors:  Rutger A Middelburg; M Sesmu Arbous; Judith G Middelburg; Johanna G van der Bom
Journal:  Clin Epidemiol       Date:  2018-10-03       Impact factor: 4.790
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.